Does bivalirudin reduce the composite of death, myocardial infarction, or major bleeding in patients undergoing PCI for myocardial infarction compared to heparin monotherapy?
In patients undergoing PCI for myocardial infarction, bivalirudin does not provide a significant advantage over heparin monotherapy for the composite of death, MI, or major bleeding.
Among patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy. (Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART ClinicalTrialsRegister.eu number, 2012-005260-10 ; ClinicalTrials.gov number, NCT02311231 .).
Erlinge et al. (Sun,) studied this question.